What's Hot & What's Not in Antibody-Drug Conjugates (ADC) Licensing

Antibody-Drug Conjugates combine the specificity of the antibody recognizing the antigen target with the potent tumor-killing effects of a cytotoxic, attached typically via a linker. 6 ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by 2024 (GlobalData). Currently, about 100 ADCs are in clinical development.  
In this discussion, our expert panel addressed the following questions:

  • What targets are suitable?
  • What are the trends in linkers and the drugs to be attached to the antibodies? What are the indications being pursued?
  • How are companies dealing with the complexities of internalization and the high cost of goods? What kind of data will drive an ADC licensing deal?
  • How do the ADCs fit in the world of immuno-oncology?
  • What is the future for ADCs?

The virtual discussion was moderated by biopharma partnering expert, Linda Pullan, Ph.D., of Pullan Consulting along with Jeff Bockman, Ph.D., the EVP and Head of the Oncology Practice for Cello Health BioConsulting, formerly Defined Health. The panel featured ADC experts who provided unique insight and a look into the challenges and future of ADCs.

 


WATCH THE
WEBINAR


ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives organizations of all sizes in all industries the confidence to simply and securely share sensitive documents with third parties during due diligence, fundraising, board communications, and any circumstance when it is crucial that confidential information is maintained under the highest level of security and control.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.

THE PANEL:

Company team

Linda Pullan, Ph.D.

Pullan Consulting

Linda and her team at Pullan Consulting offer biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a  PhD  in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals.  Learn More

Company team

Jeff Bockman, Ph.D.

EVP & Head of Oncology Practice, Cello Health BioConsulting, formerly Defined Health

Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting, formerly Defined Health. He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn More

Company team

Peter Dragovich, Ph.D.

Staff Scientist, Genentech

Peter Dragovich received a BS in chemistry from UC Berkeley and subsequently obtained a Ph.D. in synthetic organic chemistry from Caltech under the direction of Professor Andrew Myers. He has worked in the pharmaceutical industry for more than 25 years in both large pharma and biotech organizations and has performed a variety of research and management activities during that time. He contributed to the discovery and development of several antiviral agents that progressed to human clinical testing including the rhinovirus protease inhibitors Rupintrivir (AG-7088) and AG-7404 as well as the HCV polymerase inhibitors Filibuvir (PF-00868554) and Setrobuvir (ANA-598). He joined Genentech in 2010 and has since worked on multiple projects in both the immunology and oncology therapeutic areas. His Genentech activities include leading the company’s efforts to identify novel payloads and linkers that can be utilized for the creation of new antibody-drug conjugates. His current research interests entail the targeted delivery of novel cargos via antibody-mediated technologies.

Company team

Neela Patel, Ph.D.

Executive Director of Business Development, Seattle Genetics

Neela Patel joined Seattle Genetics as Executive Director of Business Development in May 2016, with responsibility for identification, evaluation, and transaction of collaboration, licensing, and acquisition opportunities to diversify the pipeline. Previously, at AbbVie she identified, introduced, and led technical diligence, resulting in more than twenty-five executed deals including collaborations, licensing, and participation in consortia. Dr. Patel spent the first 16 years of her career in drug discovery management positions of increasing responsibility to advance small molecules and biologics from early stage discovery through IND filing at Poniard Pharmaceuticals, Genentech, SUGEN/Pharmacia, and Roche Bioscience.

Company team

Jason Kim

President & COO, Molecular Templates

Jason Kim joined Molecular Templates in 2010 and serves as President and Chief Operating Officer. He has 16 years of experience in the biotechnology industry including operations, business development, and venture capital. He previously led corporate development and strategic planning initiatives at OSI Pharmaceuticals and ImClone Systems. He served as an investment professional at Domain Associates where he focused on venture and public investments in biotechnology. Mr. Kim holds an MBA from The Wharton School and a BA in Neuroscience from Wesleyan University.

OUR SPONSORs: 

Demo Logo
Demo Logo
Demo Logo